Ignite Creation Date:
2025-12-24 @ 6:41 PM
Ignite Modification Date:
2026-01-02 @ 6:03 PM
Study NCT ID:
NCT02207257
Status:
COMPLETED
Last Update Posted:
2020-05-21
First Post:
2014-07-28
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study of PER977 Administered to Subjects With Steady State Edoxaban Dosing and Re-anticoagulation With Edoxaban
Sponsor:
Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2014-03
Start Date Type:
None
Primary Completion Date:
2015-09
Primary Completion Date Type:
ACTUAL
Completion Date:
2015-11
Completion Date Type:
ACTUAL
First Submit Date:
2014-07-28
First Submit QC Date:
None
Study First Post Date:
2014-08-04
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
2017-10-02
Disp First Post Date Type:
ACTUAL
Last Update Submit Date:
2020-05-19
Last Update Post Date:
2020-05-21
Last Update Post Date Type:
ACTUAL